Business Context and Reporting Period
This Form 8-K is filed by Lunai Bioworks Inc. (LNAI), a Delaware corporation, for the reporting period ending February 17, 2026. The filing addresses a critical corporate governance event regarding the company's listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory listing status and does not contain financial performance data.
Material Changes
- Delisting Notice: On February 6, 2026, the company received a determination from the Nasdaq Listing Qualifications Staff to delist its securities.
- Appeal Granted: On February 17, 2026, the Nasdaq Hearings Panel granted the company's request for a hearing to appeal the delisting determination.
- Stay of Action: The delisting action is currently stayed pending the final written decision from the Panel.
Outlook, Risks, and Management Commentary
Hearing Schedule: The appeal hearing is scheduled for March 26, 2026.
Risks and Contingencies: Management explicitly states there can be no assurance that the Panel will grant the request for continued listing or that the company will be able to maintain compliance with Nasdaq's continued listing requirements. The outcome remains uncertain.
Investor Verification Checklist
- Verify the specific Nasdaq listing rule or standard the company failed to satisfy (not detailed in this text).
- Monitor the outcome of the hearing scheduled for March 26, 2026.
- Check for subsequent filings regarding the company's compliance plan or financial status leading up to the hearing.
- Confirm if the stock remains tradable on Nasdaq during the stay period.